Citigroup Inc T Scan Therapeutics, Inc. Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 1,088 shares of TCRX stock, worth $1,349. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,088
Previous 11,772
90.76%
Holding current value
$1,349
Previous $17,000
94.12%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding TCRX
# of Institutions
78Shares Held
38.2MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$9.74 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$6.48 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$5.53 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$3.45 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$2.87 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $23.5M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...